Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
The development of subclinical DIC in a patient with factor IX hemophilia receiving concentrate replacement therapy during surgery is discussed with respect to pertinent laboratory features. Subsequent thromboembolic phenomena are presented in the context of current literature. Of significance is the failure of heparin given with the factor IX concentrate to prevent DIC. The value of adequate laboratory monitoring during therapy is stressed.
D000328:Adult; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D005164:Factor IX / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D013923:Thromboembolism / Q000209:etiology*
D005164:Factor IX